{"id":624206,"date":"2022-11-07T18:28:02","date_gmt":"2022-11-07T18:28:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=624206"},"modified":"2022-11-07T18:28:02","modified_gmt":"2022-11-07T18:28:02","slug":"pd1-and-pdl1-inhibitors-competitive-landscape-report-2022-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pd1-and-pdl1-inhibitors-competitive-landscape-report-2022-by-delveinsight_624206.html","title":{"rendered":"PD-1 and PD-L1 Inhibitors Competitive landscape report 2022 by DelveInsight"},"content":{"rendered":"
\n
\"PD-1<\/a><\/div>\n
\n
PD-1 and PD-L1 Inhibitors Competitive landscape<\/div>\n<\/div>\n<\/div>\n
PD-1 and PD-L1 Inhibitors pipeline constitutes 180+ key companies continuously working towards developing 200+ PD-1 and PD-L1 Inhibitors treatment therapies, analyzes DelveInsight<\/div>\n

Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune responses and promoting self-tolerance through modulating the activity of T-cells, activating apoptosis of antigen-specific T cells and inhibiting apoptosis of regulatory T cells. Programmed Cell Death Ligand 1 (PD-L1) is a trans-membrane protein that is considered to be a co-inhibitory factor of the immune response, it can combine with PD-1 to reduce the proliferation of PD-1 positive cells, inhibit their cytokine secretion and induce apoptosis. PD-L1 also plays an important role in various malignancies where it can attenuate the host immune response to tumor cells.<\/p>\n

 <\/p>\n

DelveInsights, “PD-1 and PD-L1 Inhibitors Competitive landscape, 2022<\/strong>” report provides comprehensive insights about 180+ companies and PD-1 and PD-L1 Inhibitors drugs in PD-1 and PD-L1 Inhibitors inhibitors Competitive landscape. It covers the therapeutics assessment by product type,stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n

 <\/p>\n

To know more about the PD-1 and PD-L1 Inhibitors Pipeline report, click here: PD-1 and PD-L1 Inhibitors Competitive landscape<\/a><\/strong><\/p>\n

 <\/p>\n

Key Takeaways from the PD-1 and PD-L1 Inhibitors Competitive landscape report:<\/strong><\/p>\n